The Influenza Vaccines Market is predicted to reach US$ by 2030 from US$ 6.9 billion in 2021, and to grow at a CAGR of 7.5% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Vaccine Type (Live Attenuated and Inactivated), by Valency (Quadrivalent and Trivalent), by Age Group (Pediatrics and Adults), by Distribution Channel (Hospital Pharmacy and Government Suppliers)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
By Vaccine Type (Live Attenuated and Inactivated), by Valency (Quadrivalent and Trivalent), by Age Group (Pediatrics and Adults), by Distribution Channel (Hospital Pharmacy and Government Suppliers)
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Influenza Vaccines - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Influenza Vaccines - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Influenza Vaccines - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Influenza Vaccines - ANALYSIS & FORECAST, BY REGION
North America Influenza Vaccines
1. North America Influenza Vaccines , by Country
1. US
2. Canada
1. North America Influenza Vaccines , by Product
2. North America Influenza Vaccines , by Type
3. North America Influenza Vaccines , by Gender
4. North America Influenza Vaccines , by Sales Channel
3. Europe Influenza Vaccines
1. Europe Influenza Vaccines , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Influenza Vaccines , by Product
3. Europe Influenza Vaccines , by Type
4. Europe Influenza Vaccines , by Gender
5. Europe Influenza Vaccines , by Sales Channel
4. Asia Pacific Influenza Vaccines
1. Asia Pacific Influenza Vaccines , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Influenza Vaccines , by product
3. Asia Pacific Influenza Vaccines , by Type
4. Asia Pacific Influenza Vaccines , by Gender
5. Asia Pacific Influenza Vaccines , by Sales Channel
5. Rest of the World Influenza Vaccines
1. Rest of the World Influenza Vaccines , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Influenza Vaccines , by Product
3. Rest of the World Influenza Vaccines , by Type
4. Rest of the World Influenza Vaccines , by Gender
5. Rest of the World Influenza Vaccines , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 89